Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy

British Journal of Haematology

Volumn 95, Issue 2, 1996, Pages 241-248

  Kling, Pamela J ^a,c   Dragsten, Paul R ^d   Roberts, Robin A ^a   Dos Santos, Betty ^b,c   Brooks, Donald J ^b,c   Hedlund, Bo E ^d   Taetle, Raymond ^b,c  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d Biomedical Frontiers Inc   (United States)

Author keywords

Anaemia; Chelation; Erythropoiesis; Iron blockade; Transferrin receptor

Indexed keywords

DEFEROXAMINE; DEFEROXAMINE HYDROXYETHYL STARCH; ERYTHROPOIETIN; HETASTARCH; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CONTROLLED STUDY; ERYTHROPOIESIS; HEPATOMA CELL; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029823102     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1919.x     Document Type: Article

References (30)

1. Balkwill, F., Burke, F., Talbot, D., Tavernier, J., Osborne, R., Naylor. S., Durbin, H. & Fiers, W. (1987) Evidence for tumour necrosis factor/cachectin production in cancer. Lancet, ii. 1229-1232.
2. Balla, G., Vercellotti, G.M., Muller-Eberhard, U., Eaton, J. & Jacob, H.S. (1991) Exposure of endothelial cells to free heme potentiates damage mediated by granulocytes and toxic oxygen species. Laboratory Investigation, 64, 648-655.
3. Bray, G., Taylor, B. & O'Donnell, R. (1992) Comparison of the erythropoietin response in children with aplastic anemia. transient erythroblastopenia, and iron deficiency. Journal of Pediatrics, 120, 528-532.
4. Brooks. D., Taylor. C., Dos Santos, B., Linden, H., Houghton, A., Hecht, T.T., Kornfeld, S. & Taetle, R. (1995) Phase Ia trial of murine IgA anti-transferrin receptor antibody 42/6. Clinical Cancer Research, 1. 1259-1265.
5. DeMarchi, S., Pirisi, M. & Ferraccioli, G. (1993) Erythropoietin and the anemia of chronic diseases. Clinical and Experimental Rheumatology, 11, 429-444.
6. Dragsten, P., Hallaway, P., Hanson, G., Kling. P. & Hedlund, B. (1994) First use of a novel high molecular weight iron chelator in humans. (Abstract). Blood, 84, 259a.
7. Faquin, W.C., Schneider, T.J. & Goldberg, M.A. (1992) Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood, 79, 1987-1994.
8. Feelders, R.A., Vreugdenhil, G., Manger, B., van EiJk, H.G. & Swaak, A.J.G. (1994) Serum transferrin receptor levels in anaemia of rheumatoid arthritis and effects of iron chelation treatment. European Journal of Haematology, 52, 61-62.
9. Garcia, J.F., Ebbe, S.N., Hollander, L., Cutting, H.O., Miller, M.E. & Cronkite, E.F. (1982) Radioimmunoassay of erythropoietin: circulating levels in normal and polycythemic human beings. Journal of Laboratory and Clinical Medicine, 99, 624-635.
10. Georgieff, M.K., Landon, M.B., Mills, M.M., Hedlund, B.E., Faassen. A.E., Schmidt, R.L., Ophoven, J.T. & Widness, J.A. (1990) Abnormal iron distribution in infants of diabetic mothers: spectrum and maternal antecedents. Journal of Pediatrics, 117, 455-461.
11. Gleadle, J.M., Ebert, B.L., Firth, J.D. & Ratcliffe, P.J. (1995) Regulation of angiogenic growth factor expression by hypoxia. transition metals, and chelating agents. American Journal of physiology, 268 (Cell Physiology, 37). C1362-C1368.
12. Goldberg, M.A, Dunning, S.P. & Bunn, H.F. (1988) Regulation of the erythropoietin gene: evidence that the oxygen sensor is a heme protein. Science, 242, 1412-1415.
13. Hallaway, P.E., Eaton, J.W., Panter, S.S. & Hedlund, B.E. (1989) Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers. Proceedings of the National Academy of Sciences of the United States of America, 86, 10108-10112.
14. Halliwell, B. (1994) Iron, oxidative damage, and chelating agents. The Development of Iron Chelators for Clinical Use (ed. by R. Bergeron and G. Brittenham), pp. 33-56. CRC Press, Boca Raton.
15. Jelkmann, W., Wolff, M. & Fandrey, J. (1990) Modulation of the production of erythropoietin by cytokines: in vitro studies and their clinical implications. Contributions to Nephrology, 87, 68-77.
16. Johnson, R.A. & Roodman, G.D. (1989) Hematologic manifestations of malignancy. Diseuse a Month, 35, 727-768.
17. Joosten, E., Van Hove, L., Lesaffre, E., Goossens, W., Dereymaeker, L., Van Goethem, G. & Pelemans, W. (1993) Serum erythropoietin levels in elderly inpatients with anemia of chronic disorders and iron deficiency anemia. Journal of the American Geriatric Society, 41, 1301-1304.
18. Klausner, R.D., Rouault, T.A. & Harfor, J.B. (1993) Regulating the fate of mRNA: the control of cellular iron metabolism. Cell, 72, 19-28.
19. Mosmann, T. (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
20. Pippard, M. (1994) Iron chelation therapy in the treatment of iron overload. The Development of Iron Chelators for Clinical Use (ed. by R. Bergeron and G. Brittenham). pp. 57-74. CRC Press, Boca Raton.
21. Ponka, P. (1994) Physiology and pathophysiology of iron metabolism: implications for iron chelation therapy in iron overload. The Development of Iron Chelators for Clinical Use (ed. by R. Bergeron and G. Brittenham). pp. 1-32. CRC Press, Boca Raton.
22. Semenza, G.L. & Wang, G.L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Molecular und Cellular Biology, 12, 5447-5454.
23. Skikne, B. (1987) A commercial electrochemical method evaluated for measurement of iron status. Clinical Chemistry, 33, 1645-1647.
24. Taetle, R., Rhyner, K., Castagnola, J., To. D. & Mendelson, J. (1985) Role of transferrin, Fe and transferrin receptors in myeloid leukemia cell growth: studies with an anti-transferrin receptor monoclonal antibody, Journal of Clinical Investigation, 75. 1061-1067.
25. Trowbridge, I.S. & Lopez. F. (1982) Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proceeding of the National Academy of Sciences of the United States of America, 79, 1175-1179.
26. Vreugdenhil, G., Feelders, R., Coppens. P.J.W. & deLeeuw, P.W. (1992) Possible mechanisms underlying potentiating effects of iron chelators in hematopoietic response to erythropoietin. Nephron, 61, 475-476.
27. Vreugdenhil, G., Kontoghiorghes, G.J., Van Eijk, H.G. & Swaak. A.J.G. (1991) Impaired erythropoietin responsiveness to the anaemia in rheumatoid arthritis: a possible inverse relationship with iron stores and effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one. Clinical and Experimental Rheumatology, 9, 35-40.
28. Vreugdenhil, G., Smeets, M., Feelders, R.A. & van Eijk, H.G. (1993) Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematologica, 89, 57-60.
29. Wang, G.L. & Semenza, G.L. (1993) Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor-1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 82, 3610-3615.
30. White, S., Taetle, R., Seligman, P.A., Rutherford, M. & Trowbridge, I.S. (1990) Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Research, 50, 6295-6301.